{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-040073","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.707938+00:00","generated_at":"2026-05-31T05:23:52.304773+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InfuSystem and Sanara secure exclusive US distribution deal for ChemoMouthpiece oral cryotherapy device","bullets":["SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.","Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece; SI Technologies has a purchase option on the US business through January 2029.","Product targets 500,000–1,000,000 annual oral mucositis patients; estimated US market exceeds $600 million.","InfuSystem's existing oncology sales force will market the device to ~3,000 cancer centers.","AMA issued a new CPT code (effective July 2024) for reimbursement of the oral cryotherapy procedure."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-040073","json":"https://secwatch.observer/filing/0001628280-24-040073.json","markdown":"https://secwatch.observer/filing/0001628280-24-040073.md","text":"https://secwatch.observer/filing/0001628280-24-040073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/0001628280-24-040073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/infu-20240911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:23:52.304773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}